Sirtex completes recruitment for SIR-Spheres trial
Sirtex Medical (ASX:SRX) has completed patient recruitment for its latest trial of its SIR-Spheres microspheres, its targeted radiation therapy for liver cancers.
The FOXFIRE Global trial will evaluate combining SIR-Spheres Y-90 resin microspheres with standard of care chemotherapy in first-line metastatic colorectal cancer patients with inoperable liver metastases.
It will compare the results of combining microspheres with chemotherapy against chemotherapy alone.
Combined with its SIRFLOX and FOXFIRE clinical studies, over 1000 patients have been recruited globally. Over 200 of these have been enrolled in the FOXFIRE Global study.
The primary overall survival endpoint from the combined trials is expected to be available during the first half of 2017.
“We are delighted to have completed recruitment of our FOXFIRE Global clinical study on schedule, with the total number of patients recruited ahead of initial expectations under the study design,” Sirtex CEO Gilman Wong said.
“This study, when combined with the [others], will generate sufficient statistical power to determine whether SIR-Spheres microspheres in combination with existing chemotherapy can increase OS in a clinically significant manner in these patients versus chemotherapy alone.”
Sirtex Medical (ASX:SRX) shares were trading 1.52% higher at $28.04 as of around 2.30 pm on Friday.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
